NOTTINGHAM, England and DE SOTO, Kansas, March 3, 2016 /PRNewswire/ --
U.S.-based Stroke Detection Plus® to offer Oncimmune's EarlyCDT®-Lung, a blood test to aid in the risk assessment and early detection of lung cancer
Oncimmune, a leader in early cancer detection, today announced a partnership with Stroke Detection Plus® (SDP), a leading provider of cardiovascular and corporate wellness screenings in the US. Stroke Detection Plus and its wellness division, Health Gauge, will offer Oncimmune's EarlyCDT®-Lung test to its clients which include large employers, unions and individuals.
EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer. The test measures a panel of seven autoantibodies to detect the presence of lung cancer and has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
Stroke Detection Plus/Health Gauge is a widely respected provider of onsite preventive screenings including stroke risk assessment screenings, health risk assessments, biometric screenings, bloodwork packages, health coaching programs and a variety of other solutions. Headquartered in Des Moines, Iowa, Stroke Detection Plus/Health Gauge is an onsite preventative screening company servicing the Upper Midwest. Stroke Detection Plus has helped thousands of clients gain control of their health and avoid serious medical complications. Each mobile team is equipped to screen clients for cardiovascular disease and other leading causes of chronic diseases. Stroke Detection Plus provides fast and affordable screenings to their growing community of clients.
EarlyCDT-Lung will be ordered by a physician for those at high risk of lung cancer, based upon smoking habits, family history and exposure to known carcinogens.
Greg Stanley, President of Commercial Operations, Oncimmune said: "This partnership with Stroke Detection Plus will bring EarlyCDT-Lung to new people and provide them with information that could positively impact their health. The agreement also highlights the potential of EarlyCDT-Lung as an addition to wellness programs for benefits consultants and managed care organizations."
EarlyCDT-Lung is being used in the world's largest randomised trial for the early detection of lung cancer using biomarkers ever conducted; the National Health Service (NHS) Scotland ECLS study of more than 10,000 high-risk smokers. Early results were recently presented at the 16th World Conference on Lung Cancer; showing a high cancer detection rate with the majority of these cancers being early stage, resulting in better than expected test performance.
Oncimmune is an industry leader in early cancer detection. The company has pioneered the development of autoantibody assay technologies that have the potential to allow earlier cancer detection than other methods and can be applied to a very wide range of solid tumour types. The Company's proprietary EarlyCDT technology platform was launched in 2009 and EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT tests for liver and ovarian cancer are in final validation.
Oncimmune is headquartered in Nottingham, United Kingdom with testing facilities in the US.
For more information: http://www.oncimmune.com
Chris Gardner, Matthew Neal, Lindsey Neville
Consilium Strategic Communications
+44 (0) 20 3709 5813